The Surprising Surge in One-Time Titans and the Weight-Loss Drugmaker at All-Time Highs 3/29/23
CNBC's "Fast Money"
00:00
The Novo Trial Results Mean for the Weight Loss Market
Most of the tolerability issues are things like nausea and GI side effects. Viking Therapeutics getting in apparently to that market. Jared Holtz, health care equity strategist with Mizzou Ho: Very rosy picture painted by Novo execs.
Play episode from 28:05
Transcript
